VHL-deficient renal cancer cells gain resistance to mitochondria-activating apoptosis inducers by activating AKT through the IGF1R-PI3K pathway

Targeting cholesterol with β-cyclodextrin sensitizes cancer cells for apoptosis

(2015) Ryuji Yamaguchi et al.   FEBS LETTERS

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice

(2015) Jianhui Chang et al.   NATURE MEDICINE

Dynamic oxygenation measurements using a phosphorescent coating within a mammary window chamber mouse model

(2015) Rachel Schafer et al.   Biomedical Optics Express

Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal Tumor

(2015) Thomas Mühlenberg et al.   PLoS One

ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21(CIP1/WAF1)in human cancer cells

(2014) Jingru Li et al.   BRITISH JOURNAL OF PHARMACOLOGY

Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor

(2014) T. S. Kim et al.   CLINICAL CANCER RESEARCH

Challenges in targeting cancer metabolism for cancer therapy

(2012) Ryuji Yamaguchi et al.   EMBO REPORTS

Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib

(2011) F Di Fiore et al.   BRITISH JOURNAL OF CANCER

Finding a Panacea among Combination Cancer Therapies

(2011) R. Yamaguchi et al.   CANCER RESEARCH

Binding between Insulin-like Growth Factor 1 and Insulin-like Growth Factor-binding Protein 3 Is Not Influenced by Glucose or 2-Deoxy-d-glucose

(2011) Matei Mireuta et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1

(2011) Luke R.E. Harrison et al.   JOURNAL OF CLINICAL INVESTIGATION

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

(2010) Scott Ackler et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R

(2009) Diansheng Zhong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Repetitive Hypoxic Preconditioning Attenuates Renal Ischemia/Reperfusion Induced Oxidative Injury via Upregulating HIF-1α–Dependent bcl-2 Signaling

(2009) Chih-Ching Yang et al.   TRANSPLANTATION

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2

(2008) Alfredo Toschi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY